A detailed history of L2 Asset Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, L2 Asset Management, LLC holds 1,653 shares of VRTX stock, worth $826,301. This represents 0.24% of its overall portfolio holdings.

Number of Shares
1,653
Previous 2,394 30.95%
Holding current value
$826,301
Previous $1 Million 22.6%
% of portfolio
0.24%
Previous 0.34%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $291,072 - $359,777
-741 Reduced 30.95%
1,653 $774,000
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $274,375 - $300,211
673 Added 39.11%
2,394 $1 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $256,564 - $307,188
748 Added 76.88%
1,721 $700,000
Q3 2023

Nov 08, 2023

SELL
$338.18 - $362.46 $735,879 - $788,712
-2,176 Reduced 69.1%
973 $338,000
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $47,163 - $52,786
150 Added 5.0%
3,149 $1.11 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $429,093 - $489,496
1,515 Added 102.09%
2,999 $944,000
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $58,599 - $65,383
214 Added 16.85%
1,484 $430,000
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $298,399 - $371,538
1,270 New
1,270 $358,000
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $601,186 - $700,764
-2,904 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $95,017 - $126,725
459 Added 18.77%
2,904 $686,000
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $625,064 - $741,079
2,445 New
2,445 $665,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $128B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track L2 Asset Management, LLC Portfolio

Follow L2 Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of L2 Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on L2 Asset Management, LLC with notifications on news.